About Adial Pharmaceuticals, Inc.
https://www.adialpharma.comAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
CEO
Cary John Claiborne MBA
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-08-07 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
GEODE CAPITAL MANAGEMENT, LLC
Shares:164.13K
Value:$36.65K
VANGUARD GROUP INC
Shares:156.02K
Value:$34.84K
CITADEL ADVISORS LLC
Shares:143.79K
Value:$32.11K
Summary
Showing Top 3 of 21
About Adial Pharmaceuticals, Inc.
https://www.adialpharma.comAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.76M ▼ | $-1.79M ▲ | 0% | $-0.08 ▲ | $-1.79M ▲ |
| Q2-2025 | $0 | $1.88M ▼ | $-1.96M ▲ | 0% | $-0.18 ▲ | $-1.88M ▲ |
| Q1-2025 | $0 | $2.27M ▲ | $-2.23M ▼ | 0% | $-0.34 ▼ | $-2.27M ▼ |
| Q4-2024 | $0 | $1.94M ▼ | $-2.07M ▲ | 0% | $-0.11 ▲ | $-2.07M ▲ |
| Q3-2024 | $0 | $2.21M | $-2.19M | 0% | $-0.38 | $-2.21M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.61M ▼ | $5.66M ▼ | $1.15M ▼ | $4.51M ▼ |
| Q2-2025 | $5.91M ▲ | $6.8M ▲ | $1.21M ▼ | $5.59M ▲ |
| Q1-2025 | $2.37M ▼ | $3.45M ▼ | $1.32M ▲ | $2.13M ▼ |
| Q4-2024 | $3.75M ▼ | $5.04M ▼ | $975.86K ▲ | $4.07M ▼ |
| Q3-2024 | $5.2M | $6.71M | $829.05K | $5.88M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.79M ▼ | $-1.83M ▼ | $0 | $524.68K ▼ | $-1.31M ▼ | $-1.83M ▼ |
| Q2-2025 | $0 ▲ | $-1.75M ▼ | $0 ▼ | $5.3M ▲ | $3.55M ▲ | $-1.75M ▼ |
| Q1-2025 | $-2.23M ▼ | $-1.59M ▼ | $150K ▲ | $50.65K ▲ | $-1.38M ▲ | $-1.59M ▼ |
| Q4-2024 | $-2.07M ▲ | $-1.45M ▲ | $0 | $0 ▼ | $-1.45M ▼ | $-1.45M ▲ |
| Q3-2024 | $-2.19M | $-1.69M | $0 | $3.61M | $1.92M | $-1.69M |
CEO
Cary John Claiborne MBA
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-08-07 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
GEODE CAPITAL MANAGEMENT, LLC
Shares:164.13K
Value:$36.65K
VANGUARD GROUP INC
Shares:156.02K
Value:$34.84K
CITADEL ADVISORS LLC
Shares:143.79K
Value:$32.11K
Summary
Showing Top 3 of 21